NCT00434434View on ClinicalTrials.gov

A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma

PHASE2CompletedINTERVENTIONAL

Enrollment

61

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

June 30, 2009

Conditions

Allergic Asthma

Interventions

DRUG

omalizumab

Aged Liquid; subcutaneous repeating dose

DRUG

omalizumab

Lyophilized; subcutaneous repeating dose

DRUG

placebo

Subcutaneous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY

NCT00434434 - A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma | Biotech Hunter | Biotech Hunter